Key result
Nicardipine hydrochloride increased mean exercise duration from 5.8 to 6.6 minutes in patients with stable angina.
Why the study?
Does nicardipine hydrochloride improve exercise duration and angina symptoms in patients with stable angina?
RCT (n=46)
Double-blind
repeated cross-over
Does nicardipine hydrochloride improve exercise duration and angina symptoms in patients with stable angina?
Nicardipine monotherapy improves exercise duration in stable angina, but may precipitate unstable angina or myocardial infarction, particularly following beta-blocker withdrawal.
Answers are grounded in this paper and cite their sources.
Supports nicardipine to prolong exercise duration in stable angina; extends CCB evidence while cautioning against beta-blocker withdrawal due to ischemic events.
The effect of nicardipine hydrochloride, a calcium-channel blocking agent, was studied in 46 patients with stable angina in a double-blind, placebo-controlled, randomized, repeated cross-over protocol, using a 30 or 40 mg dose of nicardipine or placebo three times a day. Mean resting heart rate and blood pressure did not change significantly with 30 mg nicardipine; heart rate increased from 81 +/- 10 to 88 +/- 13 beats min-1, systolic blood pressure decreased from 129 +/- 18 to 119 +/- 16 mmHg, and diastolic blood pressure from 81 +/- 12 to 74 +/- 11 mmHg (P less than 0.01 for all three variables) with a 40 mg dose. Using a treadmill exercise protocol, mean exercise duration increased from 5.4 +/- 1.8 to 6.0 +/- 1.8 min (P less than 0.01) with 30 mg nicardipine, and from 5.8 +/- 1.7 to 6.6 +/- 1.9 min (P less than 0.01) with 40 mg. Time to onset of angina increased from 4.6 +/- 1.9 to 5.2 +/- 1.7 min (P less than 0.05) with 30 mg and from 5.1 +/- 1.8 to 5.7 +/- 1.8 min (P = NS) with 40 mg. Mean anginal frequency and sublingual nitroglycerin consumption were low during the cross-over placebo period and did not change significantly during therapy with nicardipine. Non-cardiac side-effects were mild and required the withdrawal of only one patient from the study. However, during nicardipine therapy four patients had unstable angina and two developed a non-Q wave myocardial infarction. Of these patients, five were receiving a beta-adrenergic blocker that was discontinued prior to the study.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Gheorghiade et al. (1989) conducted an RCT in stable angina (n=46). nicardipine hydrochloride vs. placebo was evaluated on mean exercise duration (40 mg dose) (p=<0.01). Nicardipine hydrochloride increased mean exercise duration from 5.8 to 6.6 minutes in patients with stable angina.
Synapse has enriched 10 related papers. Consider them for comparative context: